% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vonJutrzenkaTrzebiatowski:302019,
      author       = {A. von Jutrzenka-Trzebiatowski and R. Gupte and C. Daglar
                      and N. Berndt and C. Arndt and M. Bachmann$^*$ and A.
                      Feldmann$^*$},
      title        = {{C}lini{MACS} {P}rodigy {M}anufacturing of {S}witchable,
                      {AND}-{G}ate {CAR} {T} {C}ells.},
      journal      = {International journal of molecular sciences},
      volume       = {26},
      number       = {11},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2025-01217},
      pages        = {5024},
      year         = {2025},
      abstract     = {The Reverse Chimeric Antigen Receptor (RevCAR) system is an
                      adapter CAR T cell technology that allows the precise tuning
                      of T cell activity and, thus, improved safety management.
                      RevCAR T cells recognize and eradicate tumor cells via a
                      bispecific adapter molecule, termed the RevCAR Target Module
                      (RevTM). To further reduce the risk of on-target off-tumor
                      toxicities, Dual-RevCAR T cells can be employed. These cells
                      harbor two different RevCAR constructs, with the signaling
                      domain of either CD3zeta or CD28. Therefore, Dual-RevCAR T
                      cells only exert their full function when both RevCAR
                      constructs are triggered simultaneously upon recognition of
                      two different tumor antigens via RevTMs, enabling a precise
                      AND-gate targeting approach and rendering them highly
                      interesting for clinical application. For this purpose,
                      standardized and reproducible clinical-grade cell
                      manufacturing is required, for which the CliniMACS Prodigy
                      can be used. Here, we present that automated processing of
                      RevCAR and Dual-RevCAR T cells via the CliniMACS Prodigy
                      results in potent expansion, strong transduction, and a
                      favorable phenotype for clinical application. Moreover,
                      obtained cell products were highly functional in a strict
                      RevTM-dependent manner for both monospecific and AND-gate
                      targeting, clearly underlining their high potential for
                      clinical application against various tumor entities.},
      keywords     = {Humans / Receptors, Chimeric Antigen: immunology /
                      Receptors, Chimeric Antigen: metabolism / Receptors,
                      Chimeric Antigen: genetics / Immunotherapy, Adoptive:
                      methods / T-Lymphocytes: immunology / T-Lymphocytes:
                      metabolism / CD28 Antigens: immunology / CD28 Antigens:
                      genetics / CD3 Complex: immunology / CD3 Complex: genetics /
                      Neoplasms: therapy / Neoplasms: immunology / Receptors,
                      Antigen, T-Cell: genetics / Receptors, Antigen, T-Cell:
                      immunology / Antigens, Neoplasm: immunology / CliniMACS
                      Prodigy (Other) / RevCAR and Dual-RevCAR system (Other) /
                      adapter CAR T cells (Other) / tumor therapy (Other) /
                      Receptors, Chimeric Antigen (NLM Chemicals) / CD28 Antigens
                      (NLM Chemicals) / CD3 Complex (NLM Chemicals) / Receptors,
                      Antigen, T-Cell (NLM Chemicals) / Antigens, Neoplasm (NLM
                      Chemicals)},
      cin          = {DD01},
      ddc          = {540},
      cid          = {I:(DE-He78)DD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40507834},
      doi          = {10.3390/ijms26115024},
      url          = {https://inrepo02.dkfz.de/record/302019},
}